secwatch.observer — SEC 8-K summary
======================================

Issuer:     MESA LABORATORIES INC /CO/ (MLAB)
CIK:        0000724004
Form:       8-K
Filed at:   2021-12-23T23:59:59+00:00
Accession:  0001437749-21-029173
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mesa Labs announces new segment reporting structure effective Q3 FY2022
-----------------------------------------------------------------------

- Four new segments: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, Calibration Solutions.
- Clinical Genomics segment consists of recently acquired Agena Bioscience business.
- Calibration Solutions combines former Instruments and Continuous Monitoring segments.
- Over 90% of future revenues expected from pharma, medical device, and healthcare verticals.
- Change reflects management's focus on higher-growth Life Sciences Tools applications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/724004/000143774921029173/0001437749-21-029173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/724004/000143774921029173/mlab20211221_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-21-029173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer